Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Within Participant-Controlled, First-in-Human (FIH) Study to Explore the Safety, Tolerability, and Pharmacodynamic Effects of PIEZO-101, an Investigational Plasmid DNA Biostimulator Delivered by Intradermal Electroporation to the Knee and Décolleté Regions in Healthy Adult Female Participants

NCT07671027 is registered in ClinicalTrials.gov with Piezo Therapeutics, Inc. as lead sponsor.

NCT NCT07671027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Within Participant-Controlled, First-in-Human (FIH) Study to Explore the Safety, Tolerability, and Pharmacodynamic Effects of PIEZO-101, an Investigational Plasmid DNA Biostimulator Delivered by Intradermal Electroporation to the Knee and Décolleté Regions in Healthy Adult Female Participants
Lead sponsor
Piezo Therapeutics, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
August 31, 2027
Enrollment
8 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

décolleté wrinkles, left knee skin laxity, skin aging, wrinkles in decolletage, wrinkles in left knee